San Antonio Breast Cancer Symposium | Conference

Dual Therapy With Pertuzumab Slows Advanced Breast Cancer

December 9th 2011

The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.

Dr. Hortobagyi Discusses the BOLERO-2 Everolimus Trial

December 8th 2011

Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial

Exemestane Plus Everolimus New Standard of Care for Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer

December 8th 2011

The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.

Obese Patients With HER2-Positive Breast Cancer Have Worse Outcomes but Trastuzumab Equalizes Weight Differences

December 8th 2011

A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.

Dr. Perez Discusses the CLEOPATRA Pertuzumab Trial

December 8th 2011

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses the CLEOPATRA Pertuzumab Trial

The CLEOPATRA and BOLERO-2 Studies are Stirring Excitement at SABCS

December 7th 2011

The results of 2 studies likely to have a significant impact upon the treatment of women with metastatic breast cancer.

Dr. Smith on the Brachytherapy Breast Cancer Trial

December 7th 2011

Dr. Benjamin Smith from MD Anderson Cancer Center Discusses the Brachytherapy Breast Cancer Trial

New Test Predicts Recurrence Risk in Patients With Ductal Carcinoma in Situ

December 7th 2011

A new 12-gene assay for predicting risk of recurrence for patients with ductal carcinoma in situ (DCIS).

Dr. Solin Discusses the DCIS Score Recurrence Test

December 7th 2011

Dr. Lawrence Solin from Einstein Medical Center Discusses the DCIS Score Recurrence Test

Gene Signature Identifies Early Versus Late Versus No Recurrence in Hormone Receptor-Positive Breast Cancer

December 7th 2011

It may be possible to predict which women with HR+ invasive breast cancer will experience recurrence by using a series of gene expression profiles.

NEXT PAGE
PREVIOUS PAGE